
Friday, June 06, 2025 8:55:55 PM
Direct already works without surgery but if the impact is being considered as too hard and too quick then the slow walk with L first might take place but make no mistake, Direct is the disruptor that has the ability to not only affect big pharma oncology profits but also research projects and the number of surgeries done by oncologists and then beyond. The impact Direct is capable of will likely require the redirecting of research efforts to other areas of study including improving pain management, stem cell research, aerospace and environmental impact from various activities including the rapid rise of microplastics in human tissue and recovery efforts in areas poorly governed with regard to resource development. This will also allow for improving healthcare for the poor around the world with money eventually saved by governments through reduced costs to their health care agencies which can also be used to help create ongoing economic expansion and jobs that don’t put poor workers health at greater risk. We might also want to double down our efforts at stopping those that want to create bio harm to food supplies as a way to do economic and physical harm to others as the Chinese just tried to do by introducing a fungus to various grains grown in the US. Best wishes.
Recent NWBO News
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
- Investors Watching Two Small-Caps for News on Potential Major Advancements in Cancer Treatments • AllPennyStocks.com • 01/13/2025 01:56:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/26/2024 10:07:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2024 09:29:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2024 09:10:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2024 09:24:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • FITY • Jul 8, 2025 8:30 AM
Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America • AVAI • Jul 8, 2025 8:00 AM